Masaya Kino

Letter by Suwa et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial".

Journal: Circulation

Published: July 08, 2024

Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation Based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: July 08, 2024

Klebsiella Pneumoniae Invasive Syndrome With Thoracic Aortic Pseudoaneurysm.

Journal: Circulation. Cardiovascular imaging

Published: June 28, 2024

CORRIGENDUM: Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing.

Journal: Circulation reports

Published: September 11, 2023

Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing.

Journal: Circulation reports

Published: July 31, 2022

Dose adjustment based on the plasma level measurement used anti-FXa chromogenic assay on the use of non-vitamin K antagonist oral anticoagulants (NOACs) improved the overall benefit of NOACs dosing in patients with atrial fibrillation.

Journal: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology

Published: September 22, 2021

Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation　- Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: March 29, 2019

How Does the Physician Interpret the Patient's Narrative as It Relates to the Physical Exam?; Chest pain

Journal: Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine

Published: November 06, 2015

The Association between Cerebral White Matter Lesions and Plasma Omega-3 to Omega-6 Polyunsaturated Fatty Acids Ratio to Cognitive Impairment Development.

Journal: BioMed research international

Published: February 12, 2015

Letter by Suwa et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial".

Letter by Suwa et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial".

Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation Based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry.

Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation Based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry.

Klebsiella Pneumoniae Invasive Syndrome With Thoracic Aortic Pseudoaneurysm.

Klebsiella Pneumoniae Invasive Syndrome With Thoracic Aortic Pseudoaneurysm.

CORRIGENDUM: Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing.

CORRIGENDUM: Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing.

Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing.

Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing.

Dose adjustment based on the plasma level measurement used anti-FXa chromogenic assay on the use of non-vitamin K antagonist oral anticoagulants (NOACs) improved the overall benefit of NOACs dosing in patients with atrial fibrillation.

Dose adjustment based on the plasma level measurement used anti-FXa chromogenic assay on the use of non-vitamin K antagonist oral anticoagulants (NOACs) improved the overall benefit of NOACs dosing in patients with atrial fibrillation.

Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation - Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration.

Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation - Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration.

How Does the Physician Interpret the Patient's Narrative as It Relates to the Physical Exam?; Chest pain

How Does the Physician Interpret the Patient's Narrative as It Relates to the Physical Exam?; Chest pain

The Association between Cerebral White Matter Lesions and Plasma Omega-3 to Omega-6 Polyunsaturated Fatty Acids Ratio to Cognitive Impairment Development.

The Association between Cerebral White Matter Lesions and Plasma Omega-3 to Omega-6 Polyunsaturated Fatty Acids Ratio to Cognitive Impairment Development.

Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation　- Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration.

Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation　- Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration.